On January 1, Glonghui reported that Chengdu Easton Biopharmaceuticals (688513.SH) announced that by December 2024, the company repurchased 0.2222 million shares through centralized bidding, accounting for 0.1259% of the current total share capital. The highest purchase price was 30.99 yuan/share, the lowest was 29.85 yuan/share, and the total transaction amount was 6.7647 million yuan (excluding stamp duty, trading commissions, and other transaction costs).

By the end of December 2024, the company had cumulatively repurchased 3.539 million shares through centralized bidding, accounting for 2.0047% of the current total share capital. The highest purchase price was 56.05 yuan/share, the lowest was 28.12 yuan/share, and the total transaction amount was 0.13 billion yuan (excluding stamp duty, trading commissions, and other transaction costs).